T. Jurc̆ek

发表

Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

Martin Klabusay, Michael Doubek, D. Dvořáková, 2009, Experimental hematology.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

L. Dušek, H. Klamová, J. Mužík, 2013, Leukemia & lymphoma.

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

P. Valent, H. Herrmann, I. Sadovnik, 2016, Oncotarget.

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population†

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

J. Cayuela, S. Schnittger, J. Dongen, 2019, Leukemia.

Prospective analysis of low-level BCR–ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2014, Leukemia & lymphoma.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

H. Klamová, J. Moravcová, D. Dvořáková, 2010, Experimental hematology.

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

D. Colomer, J. Cayuela, S. Balabanov, 2022, Leukemia.

Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

L. Dušek, H. Klamová, J. Březinová, 2011, American journal of hematology.

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR–ABL transcript causing false-negative results by standard polymerase chain reaction

J. Mayer, F. Rázga, D. Zackova, 2010, Leukemia & lymphoma.

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

I. Glauche, H. Klamová, N. Cross, 2020, Leukemia.

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

P. Jindra, A. Folta, T. Papajík, 2024, Leukemia.